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Increased globalization of the pharmaceutical market has facilitated the unobstructed and fast spread of
poor-quality medicines. Poor-quality medicines include spurious/falsely-labeled/falsiﬁed/counterfeit
drugs (those that are deliberately and fraudulently mislabeled with respect to content and/or origin),
substandard drugs (legitimate drugs that do not meet their quality speciﬁcations), and degraded
medicines (good quality pharmaceuticals that suﬀered from deterioration caused by improper storage or
distribution). Consumption of poor-quality pharmaceuticals is likely to increase morbidity and mortality.
Moreover, poor-quality drugs can also contribute to the development of resistance to anti-infective
medicines and decrease the quality of health care received by patients. To assess the true prevalence of
poor quality drugs, tiered technology approaches enabling the testing of drug samples collected at
points of sale are required, thus ensuring public health standards. High throughput and high resolution
ambient mass spectrometry techniques allow investigation of pharmaceuticals with minimal or no
sample preparation, thus possessing capabilities to survey a large number of drug samples for their
authenticity.1. Scope of the review: background
on falsiﬁed drugs
This review discusses advances in the eld of ambient
sampling/ionization mass spectrometry (ambient MS) with a
specic focus on the detection of spurious/falsely-labeled/
falsied/counterfeit (SFFC) medicines, and provides several
examples of poor quality drugs that have been analyzed using
these approaches since 2006 (Table 1).
With the number of reports on cases involving drug coun-
terfeiting increasing globally,1 the risk to public health is at an
all-time high. The most widely used denition of counterfeit
medicines that has been used by theWorld Health Organization
(WHO) states that: “A counterfeit medicine is one which isrgia Institute of Technology, Atlanta, GA
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hemistry 2014deliberately and fraudulently mislabeled with respect to identity
and/or source. Counterfeiting can apply to both branded and
generic products and counterfeit products may include prod-
ucts with the correct ingredients, wrong ingredients, without
active ingredients, with insuﬃcient quantity of active ingredient
or with fake packaging”.2 Counterfeit drugs are the products of
criminals. Frequently, incorrect active pharmaceutical ingredi-
ents (APIs) are present in counterfeits with the purpose of
mimicking both the organoleptic characteristics or symptom-
relief eﬀects of authentic medicines, or perhaps due to the
use of waste powders le over from the manufacturing of other
pharmaceuticals.3
It has been argued that the use of the term ‘counterfeit
medicines’ and that some proposed denitions wrongly include
legitimate generics and will therefore obstruct the trade in
generic medicines by invoking intellectual property (IP) issues.4
To avoid any IP connotations the term falsied is used here
instead of counterfeit, except when this term is used in the
primary publication.5
Thorough characterization of the chemical composition of
fake medicines is of utmost importance since their consump-
tion can trigger severe side eﬀects, or even death. Falsied
medicines containing wrong APIs or insuﬃcient quantity of the
correct APIs might also be responsible for the emergence of
drug resistance, although the connection between the two has
been diﬃcult to establish. Substandardmedicines, another type
of poor quality medicine, arise as a result of lack of expertise,
poor manufacturing practices, insuﬃcient infrastructure, or inMed. Chem. Commun., 2014, 5, 9–19 | 9
Table 1 List of ambient MS techniques, their acronyms, and references of their application to the analysis of pharmaceuticals
Technique Acronym Figure Analyte Ref.
Plasma and solid–liquid extraction-based techniques
Direct analysis in real time DART 1 Artesunate 20,22 and 58
“Yaa Chud” 54
Etoricoxib 55
Alprazolam 11
Glycin, noortropyl, anapril,
mexidol, biseptol
56
Tadalal 57
Desorption atmospheric pressure chemical ionization DAPCI 2 Amoxicillin 63
Desorption atmospheric pressure photoionization DAPPI 3 Anabolic steroids 82
Desorption electrospray ionization DESI 1 Artesunate 20–22,34,58,
69 and 73
Oseltamivir 67
Laser desorption/ablation techniques
Infrared laser assisted desorption electrospray ionization IR-LADESI 4 Dihydroartemisinin,
piperaquine,
chloroquine, quinine, artesunate
87
Infrared laser ablation metastable-induced chemical ionization IR-LAMICI 5 Artesunate, acetaminophen 93
Multimode techniques
Desorption electrospray/metastable-induced ionization DEMI 6 Artesunate 94
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View Article Onlinesome cases criminal negligence.6 Degraded medicines are good
quality pharmaceuticals that suﬀered from deterioration
caused by improper storage or distribution, an issue most
commonly encountered in anti-infectives that are sold in
tropical areas.7–9
With overwhelming literature evidence, it is now well
established that drug counterfeiting is a major threat to public
health worldwide.1 This fraudulent activity not only aﬀects
consumers, but also health care providers, drug manufacturers,
and governments. Falsied medicines may be spread not only
by illegitimate channels, but also inadvertently by legitimate
channels such as through governments, private hospitals and
pharmacies. Falsied medicines may be visually indistin-
guishable from the authentic pharmaceutical product, and
licensed distributors, pharmacists, health care providers or
patients are unable to visually distinguish them.10 For example,
a recent investigation by the US Institute of Forensic Sciences
into suspicious alprazolam tablets determined that their visual
appearance mimicked the authentic product almost exactly, but
that melatonin was present instead of the correct active
ingredient.11
Although falsied drugs occur worldwide, their incidence is
greatest in regions where regulatory and enforcement systems
for medicine quality are weakest, such as developing countries
of Africa, Asia and Latin America.12 According to the latest
estimates reported by the International Medical Products Anti-
Counterfeiting Taskforce (IMPACT) set up by the WHO and
partners to ght against counterfeit medicines, it is estimated
that more than 30% of the medicines on sale in parts of Africa,
Asia and Latin America can be counterfeit. It is believed that
counterfeits make up more than 20% of the market in the
former Soviet Republics, up to 1% of sales in developed10 | Med. Chem. Commun., 2014, 5, 9–19countries, and approximately 10% in developing countries, on
average.13
According to the WHO, products that are subjected to
counterfeiting include medicines for a wide set of conditions,
ranging from the treatment of life-threatening diseases to
inexpensive versions of painkillers and antihistamines.
Amongst the most targeted medicines for counterfeiting are
those which are expensive, innovative, or in high demand, as
well as generic drugs.14 Regarding online pharmacies, over 50%
of the medicines sold over the Internet have been found to be
counterfeit.12 An alert posted by the US Food and Drug
Administration in 2010 regarding the online sale of a “generic”
version of Tamiu, which contained penicillin cloxacillin
instead of the correct API oseltamivir, is an example of such
fraudulent activities prevalent over the Internet space.
Consumption of such fake Tamiu had the potential to induce
severe allergic reactions in those allergic to penicillin.15
Medicine fraudsters prey on regions with insuﬃcient regu-
latory and legal oversight compounded with poor reporting
practices. The Pharmaceutical Security Institute (PSI), a not-for-
prot innovative pharmaceutical organization, states that
medicines in every therapeutic category are targeted by criminal
organizations with medicines in the genito-urinary and anti-
infective categories being targeted the most. PSI data also
show an increasing year-to-year trend in several other thera-
peutic categories: hormones (+76%), cytostatic (+48%), central
nervous system (+29%), musculo-skeletal (+27%), and respira-
tory (+22%). Artesunate-based antimalarials have been one of
the pharmaceuticals with the highest frequency of reported
falsication. The high incidence of malaria in many countries
of SE Asia and Africa has made this class of drugs a protable
niche for counterfeiters since 1998,8,16–19 with some estimatesThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinesuggesting that up to 33% to 53% of artesunate monotherapy
tablets were falsied.20 Artemisinin derivatives are essential for
eﬃcacious treatment of falciparum malaria. Therefore, the
dissemination of falsied antimalarials promotes avoidable
death, contributes to the growing problem of drug resistance,
reduces condence in the drug, and damages health systems
and the pharmaceutical industry.20 The potential for artemisi-
nin resistance is of major concern due to the manufacture of
medicines containing sub-therapeutic amounts of artesunate
which are probably added in order to defeat the colorimetric
methods currently used to detect artesunate.20–22
The falsication of a wide range of other essential medicines
is well-documented in the scientic literature.8,14,23,24 Some
recently reported cases include falsied Avastin used in the
treatment of cancer, which did not contain the active ingre-
dient, bevacizumab, and may have resulted in patients not
receiving needed therapy;25 Truvada and Viread, which are
pharmaceuticals used in the treatment of HIV/AIDS, and were
found to be diverted authentic products in falsied packaging;26
Zidolam-N, containing lamivudine, zidovudine and nevirapine,
also employed against HIV/AIDS, which aﬀected nearly 3000
patients that were under antiretroviral therapy;27 and an anti-
diabetic traditional medicine, which contained six times the
normal dose of glibenclamide, and led to the death of two
people, while the other nine were hospitalized.12 This evidence
strongly suggests that the proliferation of falsied drugs is a
very signicant, but neglected, public health problem. This
persistent problem has been accelerated by the globalization of
the pharmaceutical industry, which may favor the access of
criminals to technologies required to manufacture medicines
mimicking genuines.9,24
Laboratory methodologies allowing for rapid, cost eﬀective
pharmaceutical analysis are nowadays a required part of
toolbox needed to combat the ever-growing number of both
crude and sophisticated falsied medicines.20 We hypothesize
that the implementation of powerful, high throughput and
reliable technologies to screen for falsied medicines will play a
key role in providing a realistic picture of the prevalence of poor
quality medicines in the global market, identifying new fakes
and improving public health through contributing to the ght
against such criminal activities.2. Ambient ionization techniques
applied to the detection of falsiﬁed
drugs
The chemical analysis of medicines of unknown quality can be
approached by analytical methods ranging from simple thin layer
chromatography (TLC) and colorimetric tests to more sophisti-
cated ngerprinting approaches such as near-infrared spectros-
copy (NIR), Raman spectroscopy, X-ray uorescence, nuclear
magnetic resonance spectroscopy (NMR), and/or gas and liquid
chromatography coupled to mass spectrometry (GC-MS and LC-
MS, respectively) via electrospray ionization (ESI) and
atmospheric-pressure chemical ionization (APCI).8,9,14,23 GC-MS
and LC-MS enable not only the quantitation of the API amount,This journal is © The Royal Society of Chemistry 2014but also the identication of unknown sample ingredients, and are
the most commonly used techniques by laboratories in pharma-
ceutical companies and regulatory agencies in developed coun-
tries. In addition, extensive research has been conducted in recent
years to develop complementary techniques to improve the limited
sample throughput of LC and GC-MS which results from extensive
sample preparation requirements prior to analysis, and from the
length of the chromatographic runs themselves.23 With billions of
dollars of pharmaceuticals in the market and increasing fraud,
analytical technologies that can provide faster and reliable answers
in a short period of time are highly desirable.
MS is one of the most popular technologies for chemical
analysis due to its high selectivity, accuracy and quantitative
capabilities provided the investigated analytes are eﬀectively
converted to gas phase ions. Ambient ionization methods for
MS comprise a large and growing family of sampling/ionization
techniques that allow the creation of ions under ambient
conditions with minimal or no sample preparation prior to
analysis.28 Their high throughput capabilities make them
particularly suitable for the quick and reliable investigation
of large numbers of solid or liquid pharmaceutical samples of
various complexities.
Ambient ion sources operate in the open air, outside of the
mass spectrometer vacuum environment, and the analysis
probes the sample directly, without pretreatment.28 Ambient
ionization techniques share common features such as the
possibility of being interfaced with most types of mass spec-
trometers tted with atmospheric pressure interfaces, and the
ability to generate ions soly.29,30 These techniques involve
various desorption (laser, plasma, thermal, liquid jet) and
ionization (chemical ionization, electrospray, photoionization)
methods either alone or combined with each other.31
Amongst the more than 30 diﬀerent types of ambient ioniza-
tion methods reported in the last 9 years,31–33 desorption electro-
spray ionization (DESI) and direct analysis in real time (DART)
have been the two most widely adopted for detection and charac-
terization of poor-quality pharmaceutical products. Their intro-
duction in 2004 (DESI) and 2005 (DART) resulted in widespread
interest in ambient MS approaches. Besides allowing investigation
of pharmaceuticals without sample pretreatment in a few seconds,
their coupling to high resolution mass spectrometers allows the
structural identication of unknown compounds through accurate
mass and tandem MS experiments.9 Though HPLC and spectro-
photometric tests are traditionally used for analysis of known
chemicals in pharmaceutical samples, these approaches are not as
well suited for the forensic analysis of unknowns. Identifying
wrong APIs in falsied drugs, for example, is of major interest,
since their presence could be more harmful than the complete
absence of any API and also for sample ngerprinting purposes. In
this regard, ambient ionization techniques have signicantly
expanded the pharmaceutical analysis toolbox by enabling
screening, quantitation, and identication of unknowns directly
from the sample with high throughput.34
Apart from APIs, inactive excipients play a major role in any
pharmaceutical formulation during the drug development
phase. Inactive ingredients are added to drug formulations as
llers, binders, diluents, coloring agents, coatings, lubricants,Med. Chem. Commun., 2014, 5, 9–19 | 11
Fig. 1 DESI (upper) and DART (lower) analyses for ambient high-
throughput mass spectrometric analysis of unprepared samples (skin,
bricks, urine spots, clothing, tissue, etc.). Reprinted with permission
from ref. 28. Copyright © 2006, American Association for the
Advancement of Science.
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View Article Onlinedisintegrants and/or preservatives with the aim of masking their
unpleasant taste, making them easier to swallow, controlling the
API release, increasing their resistance to adverse environmental
conditions, and/or improving their appearance.35 Spectral signa-
tures of these inactive ingredients obtained through mass spec-
trometry based analytical platforms serve as forensic ngerprints
that are specic to a particular drug, and thus play a crucial role in
the quality characterization of a sample when compared against
genuine sample signatures. On the down side, these inactive
ingredients in certain cases might interfere with identication and
quantitation of chemical constituents, and may produce false
positive or false negative results. Particularly, many genuine as well
as poor-quality tablets are coated with thin polymer-based lms
that can interfere with API ionization and detection because of
charge competition and/or ionization suppression during the
ionization process. Physical removal of tablet coating prior to
ambient MS analysis is found to minimize API signal interference
from such coatings. In addition, splitting of the tablet to expose the
tablet’s core to the ionizing plume can mitigate signal masking by
surface coatings as well as any other surface contaminant. During
ambient MS analysis, it may be diﬃcult to minimize API signal
suppression due to signals from certain chemical components of a
formulation. In such cases, method development using genuine
samples is required, and statistically relevant deviation in the
forensic ngerprint from that of a genuine should be considered
as a sign of falsication, and should be subjected to further
investigations for conrmation. However, quality characterization
of a sample is always performed against a reference standard, and
the presence along with the eﬀects of these inactive ingredients on
analytical response(s) of APIs are known prior to the sample
analysis. Unknown sample characterization on the other hand
would require sample interrogation by multiple technologies
including separations prior to MS analysis for chemical identi-
cation, validation, and conrmation.2.1. Plasma and solid–liquid extraction-based techniques
2.1.1. Direct Analysis in Real Time (DART). DART (Fig. 1) is
a powerful ion source that can be employed for non-contact
analysis of solids, liquids, and gaseous samples with minimal
or no sample preparation under ambient conditions. Although
it has been combined with most types of modern mass spec-
trometers with atmospheric pressure interfaces,36–45 high
throughput applications regarding falsied drug detection have
been carried out mostly in combination with time-of-ight
(TOF) mass analyzers. This approach allows rapid identica-
tion of unknown substances with high mass accuracy along
with isotopic pattern matching and fragmentation analysis.46
The details of DART ionization are described elsewhere.30,46,47
DART uses a negatively biased point-to-plane atmospheric
pressure glow discharge to generate metastable species within
the discharge supporting gas, typically He or N2. In positive
ionization mode, protonated water clusters (the reactive
reagents) are produced by Penning ionization of atmospheric
water molecules through collision with metastables. Aer ana-
lyte thermal desorption by the heated gas stream in the region
between the DART ion source outlet and the mass spectrometer12 | Med. Chem. Commun., 2014, 5, 9–19inlet, proton transfer proceeds from the reactive reagents to the
analytes. Collisions at the atmospheric pressure inlet interface
lead to fully desolvated protonated analytes, which are trans-
ported toward the mass spectrometer inlet mainly by the gas
ow lines.48 It is believed that analyte desorption is mainly a
thermal process,49 the thermal conductivity of the gas used for
desorption being a critical parameter aﬀecting the sensitivity of
the measurements. However, it has also been suggested that
desorption of analytes might be facilitated by charged clusters
via a chemical sputtering mechanism.46,50,51 In the negative ion
generation mode, metastable atoms react with atmospheric
water to produce negatively charged oxygen-water clusters as
reactant ions that consequently interact with analyte neutrals in
the gas phase to produce negatively charged species.46 Samples
are introduced between the plasma plume and the mass spec-
trometer inlet for rapid characterization of sample chemical
composition in a single step.
Since DART is a gas phase ionization technique, formation of
complex cluster ions, metal adduct ions, and multiply charged
ions that are usually observed through solution phase ionization
techniques such as DESI (Section 2.1.3) are rarely observed.52
Relative disadvantages of DART when compared to other
ambient MS techniques include the dilution impinged in the
desorbed analyte by the discharge gas and the unavoidable ion
fragmentation observed at high discharge gas temperatures.53
DART has mainly been used for providing a rapid but qualitative
screening of pharmaceutical sample composition, but its quan-
titative capabilities still remain relatively under-explored.52
DART applications. Falsied and genuine artesunate antima-
larial tablets collected from SE Asia have been investigated by
DART MS in both negative and positive ion detection modes in
order to establish not only the presence or absence of the API,
but also the potential presence of other unstated ingredients.22This journal is © The Royal Society of Chemistry 2014
Fig. 2 Schematic of the desorption atmospheric pressure chemical
ionization experiment. Reprinted with permission from ref. 96.
Copyright © 2006, John Wiley & Sons, Ltd.
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View Article OnlineArtesunate was found to preferentially form positive ions
through adduction with ammonium ions generated in the pool
of reactant species. To eliminate false negatives and to enhance
the ionization eﬃciency of artesunate through formation of the
artesunate [M + NH4]
+ ions, the population of ammonium
reactants was increased by introduction of ammonia vapor as a
dopant in the ionization region. In this study, 83% of the
samples analyzed by DART were found to contain no detectable
artesunate. Instead, early generation antimalarials such as
pyrimethamine/sulfadoxine, chloramphenicol, and chloro-
quine; acetaminophen, metamizole, and metronidazole were
found in some tablets. Even more concerning was the detection
of a sample that contained a lower than stated quantity of arte-
sunate along with acetaminophen, which was later conrmed by
HPLC to contain only 20% of the artesunate amount expected in
the tablet. Such formulations with sub-therapeutic quantities of
API pose a grave threat to disease control as they can pass simple
colorimetric eld screening tests and thereaer be consumed by
patients in ineﬀective amounts. Such “medicines” would facili-
tate the development and propagation of drug resistant parasitic
strains and eventually render medications and disease control
eﬀorts ineﬀective.
As part of an international epidemiological collaboration
and criminal investigation focused on obtaining evidence as to
the source of falsied artesunate in SE Asia, Newton et al.
analyzed a total of 391 antimalarial samples.20 Chemical
content characterization of the samples by DART MS and DESI
MS demonstrated that 50% of the analyzed samples were not
genuine and thus of concern to public health. Samples were
found to have subtherapeutic quantities of artesunate or a wide
diversity of wrong active ingredients such as dipyrone, a variety
of antibiotics, and safrole – a banned raw material used in
manufacturing ecstasy. Hence, the nding of this wrong API
suggested links between manufacture of falsied antimalarials
and illicit drugs.
DART MS has also been applied to the identication of APIs
in tablets sold without their original packaging. For example,
when patients with fever seek treatment from private providers
in certain parts of SE Asia, they commonly opt to purchase a
little unlabeled plastic bag containing up to 8 colorful tablets
and capsules. These bags are called “Yaa chud” in the Thailand/
Myanmar border region, or “tnam psom” in Cambodia,
meaning “combination medicine” or “drug cocktails”, and are
sold without prescription or medical assessment. The content
of these cocktails is usually unknown to the patient and they are
used as the rst-line malaria treatment. Newton and co-workers
characterized 50 packets of “Yaa chud” purchased from 44
shops located in the Thailand–Myanmar border region.54
Identication of each pill was rst visually attempted by a
pharmacist, followed by chemical analysis by high resolution
DART MS and atomic spectroscopy to discover that only 14% of
the samples had the potential to cure malaria. The most
frequently detected active ingredients were acetaminophen
(22.0%), chlorpheniramine (13.4%), chloroquine (12.6%),
tetracycline/doxycycline (11.4%), and quinine (5.1%). The
potential of unregulated local practices impeding the ght
against malaria cannot be ignored and such ineﬀectiveThis journal is © The Royal Society of Chemistry 2014antimalarial drugs are likely to increase malaria morbidity,
mortality and health costs, and engender the emergence and
spread of antimalarial drug resistance. Moreover, about 82% of
the bags contained medicines that in spite of being sold to
pregnant women are contraindicated in pregnancy. Other
examples on the application of DART MS to the screening for
falsied drugs have been reported by Helmy et al. (etoricoxib),55
Samms et al. (alprazolam),11 Chernetsova et al. (glycin, noo-
tropyl, anaprilin, mexidol, and biseptol),56 and Moﬀat et al.
(tadalal).57
In forensic investigations of falsied pharmaceuticals
requiring identication and identity validation of unknown
components, the use of multiple complementary analytical
methods is oen necessary. To illustrate this multi-tiered
approach, several ambient MS techniques including DART MS
and DESI MS (see Section 2.1.3), and 2D DOSY 1H NMR were
performed to integrally characterize artesunate antimalarial
tablets collected from Burma, Cambodia and the Lao People’s
Democratic Republic (Laos). Of 16 samples only 6 were found to
have the correct API while the rest of the formulations
contained either wrong APIs such as acetaminophen or dipyr-
one, or contained only pharmaceutical excipients.58 Analytical
results from multiple techniques provided a more condent
picture on the chemical composition and homogeneity of such
samples than the one that would be obtained from the use of a
single technique.
2.1.2. Desorption atmospheric pressure chemical ioniza-
tion (DAPCI). The basic DAPCI mechanism was rst described
by Ast and co-workers, while investigating the electronic exci-
tation, surface-induced dissociation and chemical sputtering
eﬀects induced through collisions of uorocarbon ions on solid
surfaces.59 DAPCI utilizes this basic desorption and ionization
mechanism for solid sample analysis. The ion source uses a gas
ow to direct corona discharge-generated reactant ions towards
the surface of solid phase samples (Fig. 2). The gas streamMed. Chem. Commun., 2014, 5, 9–19 | 13
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View Article Onlineowing over the corona needle is doped with volatile solvent
molecules. The solvent neutrals are ionized by the corona
discharge to form the reactant ions. These reactant ions are
then directed by the gas stream at the sample. The impact of
charged particles on the sample surface induces ionization and
dislodging of charged analytes from the surface. These charged
analyte ions are then detected using a mass spectrometer with
high sensitivity, and without chemical contamination and
sample pretreatment.60
DAPCI has been applied to rapid analysis of common drugs,
common antibiotics and complex pharmaceuticals.61–63 Zang
et al. used DAPCI MS for drug quality control and chemical
origin diﬀerentiation applications. Amoxicillin capsules were
found to contain starch instead of amoxicillin. Furthermore, the
method was used to rapidly screen amoxicillin preparations,
and to discriminate between expired and unexpired drugs. This
technique also proved to be a useful alternative to track the
origin of pharmaceutical products and to diﬀerentiate their
overall quality, through chemical ngerprinting.63
2.1.3. Desorption electrospray ionization (DESI). DESI is a
powerful and minimally invasive surface characterization tool
for a wide variety of samples in the open air, with negligible
sample consumption.64 Among the broad range of demon-
strated analytical applications, both quantitative and qualita-
tive,65 DESI is particularly useful to analyze thermally labile,
nonvolatile, polar molecules in a mass range as high as 66
kDa.58,66 It has been eﬀectively utilized to detect less volatile
molecules not easily detectable by DART.21,67 Its main advan-
tages include the ability to perform chemical imaging of
surfaces, enable rapid quantitative screening, and utilize so
ionization to limit target analyte fragmentation. Its key limita-
tions include reduced analyte extraction when improper solvent
systems are used along with ion transmission that is highly
determined by a number of geometrical variables, which may
result in limited sensitivity and/or selectivity.34
In DESI (Fig. 1), a pneumatically assisted continuous elec-
trospray jet is directed towards the surface of a solid sample,
forming a micron thickness thin solvent lm on the sample
where molecules are extracted and dissolved. The solvent ow
from the spray dynamically dislodges the surface lm resulting
in the generation of analyte-containing charged secondary
droplets which are sampled downstream of the mass spec-
trometer inlet.64 Gas phase ions from secondary droplets are
formed by mechanisms similar to those in ESI.68 The signal is
inuenced by several parameters such as spray tip-to-surface
distance, sample-to-spectrometer orice distance, spray inci-
dent angle, collection angle, and sample properties such as
hardness and sample shape.69 DESI is mostly used as a surface
characterization technique because the jet of charged solvent
used to ionize the analyte dissolves a small area on the surface,
for instance, of a pharmaceutical tablet. If this action is
prolonged over time, and high repetition rate scans are
acquired, enough mass will be removed from the surface to
allow the analysis of compounds located deeper into the
sample.9
Addition of selective chemical reagents into the DESI spray
solution in order to induce selective ion–molecule reactions at14 | Med. Chem. Commun., 2014, 5, 9–19the interface between the charged microdroplets and the
condensed phase analytes is referred to as reactive DESI.21,70–72
This approach enables the analysis of materials over a large mass
range with the same sample throughput as conventional DESI,
the added advantage of improved selectivity, and likely sensitivity
enhancement due to increased ion evaporation rates and/or
reduced fragmentation brought upon by the choice of the
chemical reagent.21 This alternative allows the high throughput
screening of target species present in complex matrices avoiding
chromatographic separation by taking advantage of host–guest
chemistries and molecular recognition phenomena.67
DESI applications. The previously described DART analysis of
genuine and falsied tablets collected in SE Asia (Section 2.1.1) was
also validated by coupling DESI to ion trap MS.22 Both DESI MS
and DARTMS produced spectra with good signal-to-noise ratios in
approximately ve seconds, providing two-orders of magnitude
improvement in sample throughput over LC-MS methods.
Ricci and co-workers used micro-attenuated total reection
Fourier-transform infrared (ATR-FTIR) spectroscopic imaging,
complemented and validated by both reagentless and reactive
DESI MS in order to characterize counterfeit antimalarial
tablets collected in SE Asia.73 These two techniques were
complementary to each other in their application to tablet
quality control. ATR-FTIR allowed drug distribution imaging in
a non-destructive way, while DESI MS provided the m/z of the
spatially localized species. This approach demonstrated the
presence of dipyrone and acetaminophen in some of the fake
tablets. Although artesunate levels in genuine tablets are high
enough to allow qualitative analysis by DESI MS, substandard or
falsied tablets containing lower artesunate concentrations
may not produce a detectable signal. To increase sensitivity and
reduce ion fragmentation, a reactive DESI method was devel-
oped to detect artesunate at very low concentrations in samples
previously analyzed by HPLC. Dodecylamine was added to the
DESI spray, allowing the detection of artesunate as the proton-
bound non-covalent artesunate complex with the amine. The
identity of this adduct species was then conrmed by DESI MS/
MS.73 With this method, a sensitivity gain of up to 170-fold was
obtained in comparison to reagentless DESI, depending on
both the type of amine added to the spray and its concentration.
Reactive DESI was further exploited for the direct quantitative
analysis of APIs in antimalarials purchased from shops and
pharmacies in SE Asia. In this quantitative approach,69 the
internal standard (IS) d4-artesunic acid was synthesized, and
incorporated into a solid tablet in a controlled and well-
dispersed way, with the purpose of removing the dependences
of the analyte signal on the geometry variables of the DESI
setup. With dodecylamine as the reagent for reactive DESI, the
analyte-to-IS signal ratio was found to depend on tablet hard-
ness. A 6% precision in the amount of artesunate measured was
obtained. The precision observed was inferior to that commonly
achieved with HPLC methods (2%), but the high throughput
capability of the method easily oﬀset the somewhat reduced
precision. It was found that up to 94% quantication accuracy
could be achieved by reactive DESI.
Another reactive DESI method for direct API quantitation
purposes was reported and applied to the investigation ofThis journal is © The Royal Society of Chemistry 2014
Fig. 3 Schematic view of the DAPPI setup. Reprinted with permission
from ref. 80. Copyright © 2007, American Chemical Society.
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View Article Onlineantiviral Tamiu® samples purchased over the Internet.67 The
method was based on the formation of stable gas-phase
complexes between protonated oseltamivir and crown ethers
added to the DESI spray solvent. By allowing competition for
complex formation to take place between two diﬀerent crown
ethers, rapid and sensitive quantitation without requiring
addition of an internal standard was achieved.
DESI ambient mass spectrometry imaging (MSI) is a
versatile powerful tool that has been used to probe the spatial
resolution of analytes on the surface of intact pharmaceutical
samples with high throughput.74,75 DESI MS was performed in
the imaging mode76,77 as a tool to contrast the homogeneity in
API distribution between genuine and falsied artesunate
antimalarial tablets.58 DESI MSI not only facilitates detection
of APIs and excipients, but also detection of any minor
impurities present in the sample which would remain unde-
tected should the sample be crushed, dissolved and diluted.
Homogeneity in API distribution is highly important in certain
antimalarial therapies, in which tablets have to be split to
adjust for body weight medication dosage. DESI MS images of
genuine artesunate tablets not only showed the presence of the
correct API homogeneously distributed on the tablet, and its
absence in the fakes, but also the homogeneous distribution
of acetaminophen in the counterfeits, pointing towards
sophisticated procedures in manufacturing.
Considering that DESI MS analysis at trace levels is likely to
suﬀer from background chemical interferences arising from the
ESI-like ionization process, a platform coupling DESI to diﬀer-
ential mobility (DM) ion separation, and interfaced to a TOF
mass spectrometer (DESI-DM-MS) was developed.34 In this
approach, only ions of interest generated by DESI are trans-
mitted into the mass spectrometer for detection, allowing
discrimination and simplication of the mass spectrum by
ltering undesired chemical noise. This strategy was imple-
mented to analyze counterfeit antimalarial tablets, and
improved both the sensitivity, i.e. enhanced signal-to-noise
ratios by 70–190%, and the selectivity when compared to
standalone DESI MS.
2.1.4. Desorption atmospheric pressure photoionization
(DAPPI). In the DAPPI technique, a heated vapor jet from a
nebulizer microchip78,79 and 10 eV photons emitted by a krypton
discharge lamp simultaneously desorb and ionize analytes from
a sample surface followed by mass analysis of the produced ions
(Fig. 3).80 The microchip directs a stream of heated gas and
solvent onto the solid surface under examination. Neutral
analytes are thermally desorbed oﬀ the solid surface by a heated
gas jet (250–300 C), and the solvent spray (toluene, acetone)
mediates the atmospheric pressure photo- and chemical ioni-
zation of analytes through gas-phase chemical reactions. This
technique broadens the range of chemicals that can be ionized
by direct ionization. Due to the photon-initiated ionization
mechanisms involved and the solvent-aided analyte thermal
desorption step, both polar and nonpolar compounds are eﬃ-
ciently ionized by DAPPI.81
Kauppila et al. have applied DAPPI to the direct analysis of
illegal anabolic steroids, which are frequently sold in the black
market and online pharmacies.82,83 For analysis, an aliquot ofThis journal is © The Royal Society of Chemistry 2014the sample soaked into a kitchen paper was placed on a glass
microscope slide that was positioned under the DAPPI source
and in front of the mass spectrometer inlet. Direct analysis of
the samples by DAPPI MS and MS2 revealed the presence of
certain compounds that were not detected by traditionally
employed gas chromatographic procedures. In many cases, the
chemicals detected by DAPPI MS were diﬀerent than those
stated by the manufacturer, and the steroids detected in
seemingly identical samples were also diﬀerent.2.2. Laser desorption/ablation techniques
This subfamily of laser-based ambient two-step techniques
involves coupling of laser desorption/ablation processes to
electrospray or plasma secondary ionization. In general terms,
the plume that is generated when the surfacematerial is ablated
or desorbed by UV or IR lasers is further merged with an elec-
trospray ion plume from an electrospray source or with a reac-
tive plasma beam from a plasma source. Since desorption and
ionization events are spatially and temporally separated, these
processes can be independently optimized for selective and
sensitive measurement of semi-volatile as well as non-volatile
analytes of interest from solids and liquids.29
2.2.1. Infrared laser-assisted desorption electrospray ioni-
zation (IR-LADESI). In IR-LADESI, an IR laser is used to desorb/
ablate material from a surface under atmospheric pressure,
which is then ionized by a continuous stream of charged
droplets from an electrosprayed solution (Fig. 4).84 The neutral
plume generated by the desorption/ablation event undergoes
ion–molecule reactions with electrospray solvent ions, and/or
merges with charged electrospray droplets undergoing solvent
evaporation, charge exchange, and Coulombic explosion to
form ions.85 IR-LADESI is one of the most versatile ambient
ionization techniques for direct ionization of solid samples and
detection of semi-volatile and non-volatile chemicals.86–90 This
technique, or variations of it, have been also described by theMed. Chem. Commun., 2014, 5, 9–19 | 15
Fig. 4 Schematic of the IR LADESI ion source: ES, nanoelectrospray;
C, fused-silica capillary; HV, high voltage supply; L1, L2, and L3, pla-
noconvex lenses; A, attenuator; LT, lens tube; SP, sample plate; AA,
aqueous analyte; D1, distance between the capillary tip and ablation
point; D2, distance between the ablation point and skimmer cone; D3,
distance between the sample plate to capillary tip; h is the laser inci-
dence angle. The drawing is not to scale. Reprinted with permission
from ref. 84. Copyright © 2008, The Royal Society of Chemistry.
Fig. 5 Schematic of the IR-LAMICI ion source coupled to a quadru-
pole ion trap mass spectrometer. The inset shows the total ion current
trace observed in the analysis of a Tylenol tablet with the laser turned
oﬀ and on. Reprinted with permission from ref. 93. Copyright © 2010,
American Chemical Society.
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View Article Onlinenames electrospray-assisted laser desorption ionization
(ELDI)91 and laser assisted electrospray ionization (LAESI).92
Recently, IR-LADESI has been coupled to atmospheric pres-
sure dri tube ion mobility spectrometry (DTIMS), providing
ion mobility spectral ngerprints for medicine samples of
dubious quality.87 The technique can be applied to high-
throughput screening of pharmaceuticals, and has potential
for distinguishing between falsied and genuine medicines
rapidly. Proof of principle results were shown for the analysis of
intact antimalarial tablets collected from certain regions in SE
Asia, having piperaquine, chloroquine and artesunate as the
stated APIs.
2.2.2. Infrared laser ablation metastable-induced chemical
ionization (IR-LAMICI). IR-LAMICI is performed in an open-air
conguration, and involves coupling of IR laser ablation with
DART-type metastable-induced chemical ionization (MICI)
(Fig. 5). Gas-phase chemical ionization of neutral analytes
takes place when the surface material ablated by IR laser
pulses reacts with the metastable reactive plume of a DART-
type ion source. Analyte ions are usually protonated or
deprotonated ion species generated in positive or negative
ionization modes, respectively.93
A counterfeit artesunate antimalarial tablet collected in the
Republic of Cameroon was analyzed by IR-LAMICI in order to
explore its capabilities compared to DART and DESI.93 The
wrong active ingredient chloroquine was found in the sample as
the protonated molecule, while the expected artesunate was not
detected. This fact was conrmed by means of both DART and
DESI MS analysis. The advantage of the IR-LAMICI over DART as
an ion source lies in its ability to be used for imaging applica-
tions. Besides, there is no need for solvents as in DESI MSI.16 | Med. Chem. Commun., 2014, 5, 9–192.3. Multimode techniques
2.3.1. Desorption electrospray/metastable-induced ioniza-
tion (DEMI). Hybrid ion generation techniques based on multiple
and complementary physicochemical mechanisms allow for
simultaneous detection of a wide variety of analyte species present
in a sample, and facilitate compound identication when inves-
tigating unknowns.
DEMI is a multimode ambient source that combines the
benets of both DESI and DART-MICI.94 This ion source can be
operated in three unique modes, i.e. plasma mode (MICI-only),
spray mode (DESI-only), and dual mode (DEMI). While operation
of the ion source in the MICI-only mode allows the analysis of low-
polarity, low-molecular weight compounds, the DESI-only mode is
well suited for the analysis of high-molecular weight, high-polarity
compounds. Operation of the ion source in the DEMI mode
expands the range of target analytes that can be simultaneously
and directly detected in comparison to each of the individual
ionization sources. This approach circumvents drawbacks associ-
ated with individual techniques such as limited polarity range and
limited mass range, typical of DESI and DART. The DEMI set-up
integrates a glow discharge source that generates He meta-
stables95 with a DESI-type ion source having a resistive ow-
through heater added to the nebulizer gas line67 (Fig. 6).94 The
glass transport capillary receives the analytes that are being
transported toward the mass spectrometer inlet aer dissolution,
thermal desorption, or aerosolization by the nebulizer gas. Before
entering, the less polar molecules are chemically ionized by
mechanisms involving He metastables, in contrast to the high
polarity analytes that are ionized by DESI. The feasibility of the
DEMI ionization mechanism to provide complementary ionic
species, e.g. protonated and ammoniated species in the MICI-onlyThis journal is © The Royal Society of Chemistry 2014
Fig. 6 Schematic of the desorption electrospray/metastable induced
ionization (DEMI) ion source coupled to a quadrupole ion trap mass
spectrometer (only inlet shown). Reprinted with permission from ref.
94. Copyright © 2009, American Chemical Society.
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View Article Onlinemode, and sodiated species in the DESI-only mode, within the
same spectrum increases the identication certainty in the
screening of unknown samples. The latter fact was exemplied by
analyzing falsied artesunate tablets collected on the China/
Myanmar (Burma) border,20 which were found to contain the
wrong API artemisinin.94
3. Concluding remarks
Classication of pharmaceutical samples as genuine, substandard,
degraded or falsied is of vital importance to ensure public health.
Many examples of pharmaceutical counterfeiting as well as eﬀorts
to detect them by ambient MSmethodologies have been discussed
in this review. Drug quality surveys and forensic eﬀorts greatly
benet from the availability of high throughput ambient MS tools
which are capable of reliably screening large numbers of samples
without extensive sample preparation for the purposes of quanti-
tation and identication of unknowns. Successfully decreasing the
prevalence of poor quality drugs around the world will require
implementation of these new types of technologies for rapid
screening together with capacity building initiatives and develop-
ment of robust and aﬀordable eld screening methods.
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